Ephedrine as add-on therapy for patients with myasthenia gravis: protocol for a series of randomised, placebo-controlled n-of-1 trials

INTRODUCTION: Myasthenia gravis (MG), a rare neuromuscular disease, is often initially treated using acetylcholinesterase inhibitors. Patients who do not respond adequately depend on the use of corticosteroids or other immunosuppressive medication, but these may have serious side effects. Clinical o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMJ Open
Autors principals: Vrinten, Charlotte, Lipka, Alexander F, van Zwet, Erik W, Schimmel, Kirsten J M, Cornel, Martina C, Kuijpers, Marja R, Hekster, Yechiel A, Weinreich, Stephanie S, Verschuuren, Jan J G M
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2015
Matèries:
Neurology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4513481/
https://ncbi.nlm.nih.gov/pubmed/26185179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2015-007863
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars